Spokeswoman, Summit Advisory Board & Co-Head, IOME, Riyadh, KSA
Ida Beerhalter is Co-Head of IOME, a private investment partnership of women principals from the Gulf region with its head office in Riyadh, KSA.
Additionally, Mrs Beerhalter also serves as Member of the Board, Trustee, Advisor and Expert to various for-profit and not-for-profit organizations around the globe (amongst others Astia, Auma Obama Foundation Sauti Kuu, Omnia Strategy, First Light Trust, Women Political Leaders (WPL) Global Forum, slavefreetrade.org, Professors Without Borders, Yunus Social Business, TBLI Group The Netherlands, Charité Foundation Summit Germany). She is specialized in a wide range of issues including investing & wealth management , entrepreneurship, social business & impact investment, gender inclusiveness, women empowerment, education, emerging markets and family governance and succession planning.
CTO, Health Moonshot at Telefonica Alpha, Barcelona
For the past two decades, Alberto has been working in and speaking about tech, innovation and science. He holds a PhD in Information and Communication Technologies with a specialization in Affective Computing and Empathic Systems. Currently he is the CTO of Telefonica Alpha's Health Moonshot, where he is defining the technology strategy and overseeing the design and delivery of breakthrough solutions in digital healthcare. Prior to joining Alpha, he worked as CTO for an award-winning startup, as well as for large scale EU-funded projects.
Senior Vice President, Business Development, Cooley, Boston
Charlie Cameron has over 25 years of business development, investing and management consulting experience in more than 30 countries. His experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies, judges numerous business plan competitions and is a frequent speaker on innovation and entrepreneurship. He founded the Hub Angel Investment Group, which is on its fifth fund. He works with a plethora of entrepreneurs, innovators and investors in Europe, with special focus on DACH countries. Charlie is also Senior VP of Strategy at Cooley LLP, a global law firm with deep experience working with life science and tech companies and venture funds. He is on the board of the German American Business Council, Boston, the advisory board of the German Accelerator Life Science, and several other boards and advisory groups. During the past decade, Charlie has built a global network of entrepreneurs, investors, innovators, and others. He is a frequent speaker on panels and at forums related to venture capital and entrepreneurship. He has an MBA from MIT, an MPH from Harvard University, and a BA, Economics-honors, Phi Beta Kappa, from the University of Massachusetts.
Drs. William F. and Virginia Connolly Mitty Professor of Bioethics, Department of Population Health, New York, US
Arthur Leonard Caplan
Arthur Caplan is currently the Drs. William F. and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City. Prior to coming to NYU, he was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. He has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics; the University of Pittsburgh; and Columbia University. He received his PhD from Columbia University.
Dr. Caplan is the author or editor of thirty-five books and more than 725 papers in peer reviewed journals. His most recent books are The Ethics of Sport(Oxford University Press, 2016, with Brendan Parent) and Vaccination Ethics and Policy (MIT Press, 2017, with Jason Schwartz).
He has served on a number of national and international committees including as chair of the National Cancer Institute Biobanking Ethics Working Group, chair of the Advisory Committee to the United Nations on Human Cloning, and chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses, the special advisory committee to the International Olympic Committee on genetics and gene therapy, the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects, the Wellcome Trust Advisory Panel on Research in Humanitarian Crises, and as co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts.
He is currently the ethics advisor to the U.S. Department of Defenses’s Defense Advanced Research Projects Agency on synthetic biology, a member of the University of Pennsylvania’s External Advisory Committee for its Orphan Disease Center, a member of the Ethics and Ebola Working Group of the World Health Organization, and an advisor to the National Institutes of Health on organ transplantation. Dr. Caplan also serves as the chair of the Compassionate Use Advisory Committee (CompAC), an independent group of internationally recognized medical experts, bioethicists, and patient representatives, which advises Johnson & Johnson’s Janssen Pharmaceuticals about requests for compassionate use of some of its investigational medicines.
Dr. Caplan is a regular commentator on bioethics and health care issues for WebMD/Medscape, WGBH radio in Boston, and WMNF public radio in Tampa. He appears frequently as a guest and commentator on various other national and international media outlets.
Dr. Caplan is the recipient of many awards and honors, including a 2018 Distinguished Service Leadership Award from the Food and Drug Law Institute. In 2016, he received the Lifetime Achievement Award from the American Society for Bioethics and Humanities and the Rare Impact Award from the National Organization for Rare Disorders (NORD). In 2014 he was selected to receive the Public Service Award from the National Science Foundation/National Science Board, which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States. He received the Patricia Price Browne Prize in Biomedical Ethics for 2011.
He has also received the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. He was a USA Today 2001 “Person of the Year” and was described as one of the ten most influential people in science by Discover magazine in 2008. He has also been honored as one of the fifty most influential people in American health care by Modern Health Care magazine, one of the ten most influential people in America in biotechnology by the National Journal, one of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology, and one of the 100 most influential people in biotechnology by Scientific American magazine.
He holds seven honorary degrees from colleges and medical schools and is a fellow of the Hastings Center, the New York Academy of Medicine, the College of Physicians of Philadelphia, the American College of Legal Medicine, and the American Association for the Advancement of Science.
Senior Associate, Philips Health Technology Ventures, Amsterdam, NL
Research Affiliate, Meta Research Innovation Center at Stanford, US
Ioana Alina Cristea
Ioana Alina Cristea is Associate Professor at the Department of Clinical Psychology and Psychotherapy, Babes-Bolyai University, Romania and a Research Affiliate at the Meta-Research Innovation Center at Stanford University, USA (METRICS). She is trained as a clinical psychologist and cognitive behavioral psychotherapist and has previously worked at the Universities of Pisa and Padova, Italy, Stanford University, USA and Vrije Universiteit, Amsterdam, the Netherlands. Between 2016 and 2017, she was a Fulbright Visiting Senior Scholar at Stanford University. Her main interests relate to issues of transparency, rigor, and waste in mental health and psychological research, using both quantitative and mixed approaches. More specifically, her work focusses on critically appraising the efficacy and safety of various psychological and pharmacological interventions for mental disorders, as well as documenting the systematic effects of diverse strains of bias, such as financial and non-financial conflicts of interest.
Program Manager, Digital Health Accelerator & Community Building, Berlin Health Innovation, BIH, Berlin
Dorothy has seven years of experience supporting academic innovators and startups working in digital health, medical devices, and therapeutics. She has worked with a broad range of stakeholders such as scientists, entrepreneurs, investors, and government representatives from Germany, Europe, Israel, and the U.S. She has co-organized the Charité BIH Entrepreneurship Summit in 2017.
Before, she has been working in the field of science management and Entrepreneurship at the Leibniz-Institute for Crystal Growth, a 3D printing startup as well as Stiftung Charité and Freie Universität Berlin.
At the moment she is managing the Digital Health Accelerator Program at Berlin Institute of Health and supporting the Spark Berlin Program. Besides, she is responsible for the community building in Berlin in the field of Digital Health and is organizing a monthly event with over a hundred participants: BIH Digital Health Forum.
Dorothy is an economic historian and sociologist by training. Her thesis was focused on startups and their ways of funding in the 19th century. Moreover, she holds a Master of Public Health with core areas of cancer and cardiovascular epidemiology & systematic reviews.
Group Leader, German Center for Neurodegenerative Diseases, Berlin
Prof. Craig Garner received his doctoral degree in Biochemistry at Purdue University and did his postdoctoral studies at the Friedrich Miescher Institute in Basel, CH and was a junior group leader at the Center for Molecular Neurobiology in Hamburg. His most recent faculty appointment was at Stanford University as Professor in the Department of Psychiatry and Behavioral Science, where he co-directed the Stanford Down syndrome Center. In 2014, he became a Scientist/co-Speaker of the DZNE-Berlin: German Center for Neurodegenerative diseases and Professor at the Charité –Universitätsmedizin Berlin. In 2015, he co-founded SPARK-Berlin to help educate academic scholars about translation and entrepreneurship. He has also founded three biotech companies, “Balance Therapeuticsâ€, “Stealth Biosciencesâ€ and Navan Technologies. He maintains an active basic research program focused on the molecular and physiological mechanisms of synapse assembly and function in health and neurodegenerative diseases.
Co-Founder & CEO, Zebra Medical Vision Ltd., Israel
Mr. Gura is the CEO and Chairman of Zebra Medical Vision, a deep learning medical imaging company that will enable scalable healthcare for the 2 billion people to join the middle class by 2025. Eyal is an Angel investor and previously venture capitalist with Pitango Venture Capital, the largest venture capital fund in the Middle East. Formerly, Co-Founder: PicScout (acquired by Getty Images); PicApp (acquired by Ybrant Digital); The Gifts Project (acquired by eBay). Adviser, WebTeb.com, the leading Arabic medical portal. Member, Advisory Board, Tmura.org. Member of the Board, Latet. Founding Member, Tovanotb.org. Eyal is a faculty member at IDC's Zell entrepreneurship program and a graduate of the Wharton Business School of the University of Pennsylvania. In 2014 Eyal was named a Young Global Leader by the World Economic Forum.
Chief Business Officer, Massachusetts Biotechnology Council, Cambridge, MA
John Hallinan joined MassBio in 2012 as the Chief Business Officer and oversees the MassBio Innovation Services programs.
John's fiscal experience in the life sciences and software industries reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions.
Prior to MassBio, John was the Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio“serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur's University.
Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company's healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading pharma/bio applications and enterprise solutions supplier. As Animation Technologies' CFO, he guided the company's first and second rounds of venture funding.
John currently sits on the Advisory Board of MTTC (the MA Technology Transfer Center).
John holds a BBA from St. Bonaventure University and is a certified public accountant. He lives with his wife Denise in Marlborough, MA.
Director, Hasso-Plattner-Institut, New York
Dr. Joann Halpern is the New York Director of the Hasso-Plattner-Institut für Digital Engineering (HPI) and an Adjunct Professor of International Education at New York University. Before joining HPI, Halpern lived in Cologne, Germany and helped to prepare a new, global university for accreditation. She moved to Cologne from New York City where she was Founding Director of the German Center for Research and Innovation (GCRI).
Prior to joining the GCRI, Dr. Halpern was Director of Academic Affairs and Senior Studies and Assistant Professor of International Education at Global College of Long Island University. She also co-founded Knowledge Transfer Beyond Boundaries, an NGO with projects in Cameroon, Nigeria, and Yemen. From 1996 to 2001, Halpern was Director of International Programs at Harz University of Applied Sciences in Wernigerode, Germany. She received her B.A. from Dartmouth College, her M.A. from Harvard University, and her Ph.D. from New York University. Dr. Halpern is a recipient of the Harvard Award for Distinction in Teaching as well as scholarships and fellowships from the Fulbright Association, German Academic Exchange Service, Robert Bosch Foundation, and the National Endowment for the Humanities. She serves on the advisory boards of the Charité Entrepreneurship Summit, German Accelerator, Technical University of Dortmund, University Alliance Ruhr, and Virtual Enterprises International.
MIT Koch Institute for Integrated Cancer Research, Associate Professor of Biology, Cambridge, MA, US
Michael Hemann received his PhD from Johns Hopkins School of Medicine and performed post-doctoral work at Cold Spring Harbor Laboratory. He started his own laboratory at the Koch Institute for Integrative Cancer Research at MIT where he is currently a Professor of Biology. HiS research group has pioneered the development of novel screening strategies to characterize the genetic determinants of cancer drug action in relevant physiological settings. They have been able to extend this work into the clinic in the context of treatment refractory B cell malignancies. Their consistent objective is the development of combination drug regimens that can subvert the evolution of drug resistance.
VP, Strategy, Corporate and Business Development, Head of Immuno-Inflammation Program Unit Akili Interactive Labs, Boston, MA, US
At Akili Interactive Labs Mr. Hennemand is currently SVP of Strategy, Corporate & Business Development, Vincent is also leading the Immuno-Inflammation Therapeutic Unit. Prior his tenure at Akili, Vincent was previously VP Corporate Development and Operations at PureTech Health, the founding institution of Akili Therapeutic Labs.
Vincent spent a decade in Pharma at Sanofi Genzyme during which he had the opportunity to hold several positions from R&D, General Management, Manufacturing and Corporate Venture (SGBV) where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio and Portal Instruments. He holds an Msc in Engineering from Ecole Nationale Superieure Arts et Metiers in France, an Msc in Bioengineering from Georgia Tech, and an MBA from MIT where he received a Martin Trust Center scholarship as Healthcare Sector Practice Leader for the Institute.
Morse Barnes-Brown Pendleton, Waltham, MA, US
John Hession is a Partner and Senior Vice President, Business Development, in the Boston law firm of Morse, Barnes-Brown & Pendleton. For the last thirty-six years, John has served as a business and legal advisor to emerging-growth companies in a variety of industry sectors, ranging from life sciences, biotechnology, medical devices, and health care information software and systems, to hardware and robotics systems and software systems and services. John is also an angel investor, having invested his own capital in five venture funds and a dozen companies. During his career, John has represented more 400 companies, and for these companies he has structured and negotiated more than 375 venture capital and angel financings (debt and equity), ranging in size from $500,000 to $100 million, and representing more than $10 billion in equity and debt capital. He has also structured more than 300 acquisitions, ranging in size from $1.0 million to $4.2 billion. John's expertise also extends to joint ventures, strategic alliances, and research, development and collaboration agreements, and he has structured and negotiated more than 350 of these transactions. During his three-plus decades practicing law, John has been awarded a number of accolades, including "Best Lawyers in America" (since 2005); a "Massachusetts Super Lawyer" (since 2003); a "Top 100 Lawyers in Massachusetts" (for several years); an "IP Star" by Managing Intellectual Property magazine; and "One of Boston's Top Startup Company Lawyers" by Boston magazine. In prior life incarnations, John was also a carpenter in Ireland (High O'Neil Construction, 1974), a high school English teacher (1974-1977), and a successful computer hardware sales representative for a Fortune 50 computer manufacturer (Burroughs Corp., 1977-1979), where he was awarded Burroughs' "Legion of Honor" for being a top-performaing sales representative. Along with John Hallinan, and under the auspices of MassBio, John is the Co-Founder of the "Entrepreneurs' University", a program now in its tenth year for educating entrepreneurs in the Massachusetts Biotech Industry about the creation, financing, management, governance and growth of emerging biotech companies. Married forty-three years to his college sweetheart, John is also the proud father of three daughters in the health care profession (chemotherapy nurse, physician, speech pathologist). When he is not working, John enjoys a smooth and supple California Zinfandel, is an avid cyclist, hiker and golfer, and pursues striped bass and bluefish, fishing along the coastlines of Massachusetts.
Adjunct Associate Professor UQ Centre for Clinical Research, The University of Queensland, AUS
Dianne Jackson-Matthews is a scientist with over 30 years of experience in international regulatory affairs and bio/pharmaceutical product development. Her knowledge spans the areas of drug development and approval for biotech/biologics, biosimilars and cell and gene therapy products in the US, Europe and Australia.
Dianne is expert in the development of regulatory and technical strategies, the writing of regulatory documentation and submissions including CMC documentation, pre-clinical and clinical protocols/studies and the management of regulatory agency interactions worldwide. Dianne also has extensive experience in authoring expert reports on pharmaceutical/CMC issues, and performing regulatory and technical due diligence assessments to support funding and licensing opportunities for general industry or investment purposes.
Dianne’s skills and experience have led her to successfully become the Chief Scientific Officer at a leading international consultancy and to hold an Adjunct Associate Professor position at the University of Queensland. She is an invited speaker at national and international conferences.
Founder, eXXclaim Capital & EILSF, Los Altos, CA
Anula Jayasuriya is an experienced health care and Life Sciences executive and investor. Anula's expertise consists of a unique combination of business, basic science and medical knowledge.
Recognizing the growing yet under-invested opportunity in Women's Health, in 2013 Anula launched eXXclaim Capital, focused on catalyzing innovation, entrepreneurship and investment in this field and has already made several investments. In 2006 Anula co-founded the “Evolvence India Life Science Fundâ€ (EILSF), to make investments in pharmaceutical, biotechnology, medical device and contract services companies based in India. EILSF has garnered three successful exits to date and India Life Science 11 has had its first close.
She was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German – US venture capital firm TVM, in San Francisco. Her prior positions include VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation. Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children's Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, in England. Anula sits on the boards of Ocimum BioSolutions, and MapMyGenome, Hyderabad and nVision, San Francisco. She was previously a board member of Health Care Global which was exited to Temasek, Lipomics which was acquired by Tethys and Triesta BioSciences which was acquired by Health Care Global. She also serves on several non-profit boards, including Astia, EPPIC, and The Gruter Institute for Law and Behavioral Research.
Kennedy Family Office, US
Stephen Kennedy Smith
Stephen Kennedy Smith is a principal at the Park Agency - Joseph P. Kennedy Enterprises, the Kennedy family office, and an investor and entrepreneur. In May 2017, JFK: A Vision for America (Harper) debuts, in which Smith, President John F. Kennedy’s nephew, and renowned historian Douglas Brinkley edited.
Published in commemoration of the centennial of President John F. Kennedy’s birth, JFK brings together in one volume John F. Kennedy’s greatest speeches alongside essays by America’s top historians, analysis from leading political thinkers, and personal insights from preeminent writers and artists. Here is JFK at his best—thought-provoking, inspiring, eloquent, and wise—on a number of wide-ranging topics, including civil rights, the race to the moon, the environment, immigration, the Cuban Missile Crisis, and much more. JFK demonstrates the deep relevance of his words today and his lasting power and influence as an outstanding American leader and orator. The august list of contributors includes Secretary John Kerry, Ambassador Samantha Power, Congressman John Lewis, Senator John McCain, Senator Elizabeth Warren, His Holiness the 14th Dalai Lama, Robert Redford, Conan O’Brien, Dave Eggers, Gloria Steinem, Don DeLillo, David McCullough, George Packer, Colum McCann, Michael Beschloss, Robert Dallek, David Kennedy, Ted Widmer, Henry Louis Gates Jr., Drew Faust, Tariq Ramadan, Pastor Rick Warren, Jonathan Alter, E. J. Dionne, Ron Suskind, Paul Krugman, Kofi Annan, Governor Jerry Brown, Paul Theroux, Jorge Domínguez, and many others.
Smith is currently a lecturer at the Sloan school of Management in the visionary investing program, as well as a fellow at the Connection Science Group at MIT. He currently involved as a board member, advisory board member or partner in a number of health care and technology businesses, including, Locomobi transportation, The Marwood Group- a healthcare-focused strategic advisory firm; Pear Therapeutics, a digital health care company Resolute Bio, and New Frontier Bio. His current investment and business focus is scaling innovative healthcare, and neuroscience companies. Smith is a board member of the John F. Kennedy Library, and The Joseph P Kennedy Foundation. He also serves on the advisory board at INCAE Business School. He is cofounder and vice president of the World Leadership Alliance, an organization of business and political leaders that promotes, democracy, international understanding and trade. Smith received his BA from Harvard University, J.D. from Columbia University, and MA Ed from Harvard University School of Education. He has served on the staff of the Senate Judiciary and Foreign Relations Committees. Smith has taught in the advanced negotiation program at Harvard Law School and is a three-time recipient of the Danforth Award for excellence in teaching at Harvard University. He is also a recipient of the Lyndehurst Foundation Prize for social and artistic achievement.
Smith was Deputy Campaign Manager for Senator Edward Kennedy during his Presidential and Senatorial campaigns, Youth Coordinator for the campaign of Mario Cuomo, served on the New England Steering Committee for the Obama presidential campaign, and continues to be active in Democratic politics.
Chairman of the Managing Board of the University Medical Center Göttingen, Dean of the Faculty of Medicine, Georg‐August‐Universität Göttingen, Germany
Heyo K. Kroemer
Heyo K. Kroemer received his PhD in Pharmacology with a thesis about hemodilution treatment of stroke. Since 2012, he is full-time dean and chairman of the management board of the University Medical Center Göttingen. Before, he was professor at the University of Greifswald and served as Dean of the Medical School from 2000 to 2012. His research is about drug metabolism and transport, cardioactive substances and cytostatics, and improving drug targeting. He has published more than 270 papers.
Senior Investment Manager, High-Tech Gründerfonds Management GmbH
Lena joined High-Tech Gruenderfonds (HTGF) in 2016 and is Senior Investment Manager in the Life Science Team. She is currently responsible for ten portfolio companies in the fields of medical technology, drug development, biotechnology and digital health as well as for sourcing and completion of new early-stage investments. Before, she worked as Postdoctoral Researcher at the University Hospital in Erlangen and obtained her PhD in Immunology within a DFG-funded Fast-track PhD program at the Friedrich-Alexander University Erlangen-Nürnberg. The thesis resulted in several publications in reowned journals. Lena received her Bachelor’s degree from the Georg-August University Göttingen with studies abroad in Umeå (Sweden) and Singapore.
About HTGF - HTGF (Bonn/Berlin) is a seed investor that finances high-potential, tech-driven start-ups. With nearly EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge over 500 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and start-up experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in a range of sectors, including software, media, internet, hardware, automation, health care, chemicals and life sciences. Investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Energy, the KfW Banking Group and Fraunhofer-Gesellschaft e.V., as well as a number of well-known companies spanning all industries and segments. For more information, please visit: www.high-tech-gruenderfonds.de
Head of the Department for Digitization of Health Care at the Federal Ministry of Health, Berlin, Germany
Since April 2018, Dr Gottfried Ludewig has been Head of the Directorate-General for Digitalisation and Innovation at the German Federal Ministry of Health.
Before that, he served six years as a Member of the Berlin House of Representatives where he held the offices of Health Spokesperson and Vice-chair of the CDU Parliamentary Group.
Alongside his parliamentary mandate, he worked part-time for the management consulting firm PwC.
President of the Massachusetts Life Sciences Center and Representative of the Commonwealth of Massachusetts
Assistant Deputy Director‐General and CCIO, Queensland Health, Australia
MD, Executive Director MGH & BWH Center for Clinical Data Science Harvard Medical School, Boston, MA, US
Mark H. Michalski
Mark H. Michalski, MD,is the Executive Director of the MGH & BWH Center for Clinical Data Science,which is focused on the application and translation of novel machine learning techniques into clinicalpractice. Previous tothis role, Dr. Michalski held leadership and operational rolesat early-stagecompanies in the medical software and device domain, including Butterfly Network and HyperfineResearch.Dr. Michalski held additional strategic roles in healthcare-focused efforts at Google andGenentech.Dr. Michalski completed his radiology residency training as a Holman Fellow at Yale-NewHaven Hospital. He graduated with a degree in Cybernetics from the University of California at LosAngeles with multiple honors and received his medical degree from Stanford University.
Systemic personnel and business coach, WMC Healthcare GmbH
Marina Leonie Moskvina
Since over six years, Marina L. Moskvina works in the field of personal development and leadership behavior as well as systemic group dynamic in successful teams. After co-founding a company and leading a HR department, international experience in lecturing and workshops and a few years in the field of healthcare innovation, Mrs. Moskvina is leading the department WMC Academy within the healthcare consulting company WMC Healthcare GmbH based in Munich, focusing on change management, change behavior and leading behavior in hospitals.
Co-Founder & Managing Partner, Flying Health Incubator, Berlin
Dr. Markus Müschenich is a board certified pediatrician and holds a Master degree in Public Health. For more than 10 years he has been a board member of non-profit and private hospital groups He is founding and board member of the German Association for Internet Medicine and Venture Partner in the investment team of Peppermint Venture Partners.
Dr. Markus Müschenich is Managing Partner of the Flying Health Incubator which focuses on digital health startups developing Digital Biomarkers & Software-as-a-Drug solutions. Dr. Markus Müschenich is regarded as a specialist for digital medicine of the future.
CEO & Founder, Olaris Therapeutics, Boston, MA, US
Dr. Elizabeth O'Day is the CEO and Founder of Olaris Therapeutics, a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events and reducing unnecessary healthcare costs. Dr. O'Day is also the co-chair of the World Economic Forum’s Global Future Council on Biotechnology, she serves on the advisory board for the Precision Medicine Initiative and was an invited speaker at the annual meeting in Davos. She was also a "nominated change maker" and invited to attend the first United State of Women Summit convened by the White House in 2016. She participated in Vice President Joe Biden's Cancer Moonshot Summit to discuss collaborative ways “to end cancer as we know it.”
Dr. O’Day is also the Founder of Lizzard Fashion, an apparel company that uses fashion to promote science, and Proyecto Chispa (Project Spark), a 501c3 non-profit that recycles electronics and uses the resale of parts to build computer centers in orphanages throughout the world. Additionally, Dr. O’Day is an adjunct faculty at Boston College, teaching metabolism and entrepreneurship.
Dr. O’Day received her PhD from Harvard University, where she was a National Science Foundation fellow. She was one of 11 America scientists awarded a Winston Churchill fellowship and received a Master’s of Philosophy in Chemistry from the University of Cambridge. She has a Bachelor of Science degree from Boston College in Biochemistry, where she was awarded the Rev. Finnegan Award, the most prestigious award bestowed to an undergraduate, and nearly all of the nation’s top undergraduate research honors (Beckman scholar, Goldwater Scholar, Churchill Fellow, NSF Fellow, National Institute of Chemistry Excellence Award).
Director of the MPhil in Strategy, Marketing & Operations Programme, Cambridge Judge Business School, Cambridge, UK
Nektarios Oraiopoulos is the Director of the MPhil in Strategy, Marketing & Operations Programme and a lecturer in Operations and Technology Management at the Judge Business School, University of Cambridge. His research and teaching activities are focused on how innovative firms can improve their new product development processes: from the creation of new opportunities to better selection and successful development. His research agenda has been shaped by close collaborations with several biopharmaceutical companies and has been published in top academic journals in both the management and biopharmaceutical fields. He received his B.S. degree in electrical and computer engineering from the National Technical University of Athens, Greece and his PhD degree in management from the Georgia Institute of Technology, USA.
Co-Founder & Chief Operating Officer, Advise Connect Inspire, Cambridge, MA
Through various roles in the German and the US healthcare industries, Annika has extensive experience building strong global networks by bringing together investors, entrepreneurs, and senior industry executives. As Chief Operating Officer of ACI, she facilitates the successful US market entry of emerging companies from Europe and connects US-based startups with European investors and industry groups. Prior to joining the German Accelerator Life Sciences (GALS) and founding ACI in Cambridge, MA, Annika headed the innovation and entrepreneurship programs of Charité Foundation in Berlin, including the highly successful international healthcare industry conference, Charité Entrepreneurship Summit.
Founder and CEO of DRG - Drug Rediscovery Group Ltd, Israel
Moshe Rogosnitzky is the Founder and CEO of DRG- Drug Rediscovery Group, an Israeli-based drug development corporation that commercializes novel treatment opportunities in established drugs. Prior to founding DRG, Moshe launched Israel’s first personalized medicine consultancy, Adjuvant Medical Solutions. Over the last 20 years, Moshe has founded and co-founded numerous medical research, non-profit, and drug development corporations centered on the repurposing of established medications to create accessible and effective patient treatment solutions. Moshe’s insight and thought leadership have been recognized and called upon by researchers from the world’s leading medical institutions and universities including Massachusetts Institute of Technology, Johns Hopkins University, Penn State University, and Hadassah University Hospital. Moshe is a published researcher, inventor/patent-owner, and peer-reviewer.
SVP, Scientific & Medical Affairs Pharma & Biotech, Molecular Health, Heidelberg, Germany
Head of Life Sciences & Healthcare at Invest in Israel, Israel
CEO and Chief Medical Officer, MyWay Digital Health, Dundee, UK
Dr. Debbie Wake is CEO, clinical lead and co-founder of MyWay Digital Health (MWDH), a University of Dundee spin out company commercialising patient and clinician facing diabetes technology solutions across the UK and internatioanlly. She is also a Clinical Reader at the Centre for Medical Informatics, Usher institute, University of Edinburgh (UoE), and NHS Diabetes Consultant (NHS Lothian), (MBChB, BSc, PhD, Clin Ed Dip). She is passionate about technology, informatics and educational in diabetes care. She is national clinical lead for MyDiabetesMyWay in Scotland (>50,000 registrants), a data-driven self-management platform for people with diabetes, (winner of European e-health adopters award/ 2017 DUK self-management award) now available commercially through MWDH. She is clinical lead for an international diabetes care/ education project in China (UoE), and previously in Kuwait (University of Dundee /Dasman Diabetes Institute). She is currently leading a £1m multi-stakeholder Innovate UK Digital Health Technology Catalyst to support artificial intelligence in diabetes care. Debbie is a 2017/18 NHS Innovation Accelerator fellow, a 2015 Diabetes UK Clinical Champion. Debbie was a health columnist for the Scotsman newspaper (2008-11), and resident on-screen doctor for STV (The Hour) (2009-11). @docdebbie @MyWayDigital www.mywaydigitalhealth.co.uk firstname.lastname@example.org
Biopharmaceuticals, Clinical Compound Bank Lead, AstraZeneca Pharmaceuticals, Melbourn, UK
Andrew qualified from University of Leicester Medical School in 2000 and completed his general medical training in Leicester between 2000 and 2004. Following this, he undertook a 3-year period of research under the supervision of Sir Professor Nilesh Samani and was awarded his MD[Res] from the University of Leicester for his work on the role of endothelial progenitor cells and telomeres in coronary artery disease. Andrew completed his higher medical & cardiology training in the Wessex Deanery, and then completed two sub-specialty fellowships in advanced percutaneous coronary intervention. He was appointed consultant cardiologist in January 2015 at Kettering General Hospital. In addition to his interventional practice Andrew was the clinical lead for heart failure services and continued to pursue his interest in clinical research as an investigator on several cardiovascular trials.
Andrew moved from clinical practice into the biopharmaceutical industry in April 2016, joining AstraZeneca as Associate Director Clinical Science in the Emerging Innovations Unit based in Cambridge, UK. In this role, his primary function was to identify and develop novel drug repurposing hypotheses utilising a selection of AstraZeneca’s discontinued compounds across all therapy areas. This was predominantly done through collaborative translational and early clinical research projects involving external academic scientists and clinicians, with the aim to reanimate a discontinued compound into a full clinical development program. In Sept 2017, Andrew became a Study Physician in the translational medicine unit (TMU) within AZ’s cardiovascular, renal and metabolic disease (CVRM) unit working on a number of early clinical drug development projects in heart failure. Andrew has recently returned to the Emerging Innovations Unit as the Director Clinical Science responsible for the full repositioning clinical portfolio and supporting pre-clinical and translational projects.
Andrew has a keen interest in translational research and clinical drug development, enjoys the application of science in medicine and likes to be at the leading edge of scientific innovation. His primary interest and expertise is in cardiovascular diseases, particularly atherosclerosis, vascular/endothelial biology, coronary physiology, cardiac ischaemia/infarction, pulmonary hypertension and heart failure.